Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Treatment
30 results:

  • 1. Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer.
    Fujita KI; Matsumoto N; Murase R; Takeshima K; Ishida H; Kubota Y
    Clin Transl Sci; 2023 Oct; 16(10):1741-1747. PubMed ID: 37424405
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. RNA-seq analysis identifies transcriptomic profiles associated with anal cancer recurrence among people living with HIV.
    Ye Y; Maroney KJ; Wiener HW; Mamaeva OA; Junkins AD; Burkholder GA; Sudenga SL; Khushman M; Al Diffalha S; Bansal A; Shrestha S
    Ann Med; 2023 Dec; 55(1):2199366. PubMed ID: 37177979
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Preclinical study of T cell receptor specifically reactive with
    Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.
    Kim GB; Fritsche J; Bunk S; Mahr A; Unverdorben F; Tosh K; Kong H; Maldini CR; Lau C; Srivatsa S; Jiang S; Glover J; Dopkin D; Zhang CX; Schuster H; Kowalewski DJ; Goldfinger V; Ott M; Fuhrmann D; Baues M; Boesmueller H; Schraeder C; Schimmack G; Song C; Hoffgaard F; Roemer M; Tsou CC; Hofmann M; Treiber T; Hutt M; Alten L; Jaworski M; Alpert A; Missel S; Reinhardt C; Singh H; Schoor O; Walter S; Wagner C; Maurer D; Weinschenk T; Riley JL
    Sci Transl Med; 2022 Aug; 14(660):eabo6135. PubMed ID: 36044599
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    Carvajal RD; Nathan P; Sacco JJ; Orloff M; Hernandez-Aya LF; Yang J; Luke JJ; Butler MO; Stanhope S; Collins L; McAlpine C; Holland C; Abdullah SE; Sato T
    J Clin Oncol; 2022 Jun; 40(17):1939-1948. PubMed ID: 35254876
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells.
    Liang YH; Chen KH; Tsai JH; Cheng YM; Lee CC; Kao CH; Chan KY; Chen YT; Hsu WL; Yeh KH
    J Biomed Sci; 2021 Nov; 28(1):75. PubMed ID: 34758826
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Antigen presentation capability and AP-1 activation accompany methotrexate-induced colon cancer cell senescence in the context of aberrant β-catenin signaling.
    Dabrowska M; Uram L; Dabrowski M; Sikora E
    Mech Ageing Dev; 2021 Jul; 197():111517. PubMed ID: 34139213
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Validation of immunogenic PASD1 peptides against hla-a*24:02 colorectal cancer.
    Soh JE; Abu N; Sagap I; Mazlan L; Yahaya A; Mustangin M; Khoo TS; Saidin S; Ishak M; Ab Mutalib NS; Jamal R
    Immunotherapy; 2019 Oct; 11(14):1205-1219. PubMed ID: 31478431
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
    Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
    Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
    Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
    Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.
    Taniguchi H; Iwasa S; Yamazaki K; Yoshino T; Kiryu C; Naka Y; Liew EL; Sakata Y
    Cancer Sci; 2017 May; 108(5):1013-1021. PubMed ID: 28266765
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.
    Kijima T; Hazama S; Tsunedomi R; Tanaka H; Takenouchi H; Kanekiyo S; Inoue Y; Nakashima M; Iida M; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yamamoto S; Yoshino S; Okuno K; Nagano H
    Oncol Rep; 2017 Jan; 37(1):23-30. PubMed ID: 27878288
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.
    McCann KJ; Mander A; Cazaly A; Chudley L; Stasakova J; Thirdborough S; King A; Lloyd-Evans P; Buxton E; Edwards C; Halford S; Bateman A; O'Callaghan A; Clive S; Anthoney A; Jodrell DI; Weinschenk T; Simon P; Sahin U; Thomas GJ; Stevenson FK; Ottensmeier CH
    Clin Cancer Res; 2016 Oct; 22(19):4827-4836. PubMed ID: 27091407
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
    Hazama S; Takenouchi H; Tsunedomi R; Iida M; Suzuki N; Iizuka N; Inoue Y; Sakamoto K; Nakao M; Shindo Y; Kanekiyo S; Tokumitsu Y; Yoshimura K; Maeda N; Maeda K; Maeda Y; Matsui H; Yoshino S; Nakamura Y; Fujita Y; Hamamoto Y; Okamoto M; Fujita T; Kawakami Y; Oka M
    Anticancer Res; 2014 Aug; 34(8):4201-5. PubMed ID: 25075047
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.
    Turcotte S; Katz SC; Shia J; Jarnagin WR; Kingham TP; Allen PJ; Fong Y; D'Angelica MI; DeMatteo RP
    Cancer Immunol Res; 2014 Jun; 2(6):530-7. PubMed ID: 24894090
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study).
    Hazama S; Nakamura Y; Tanaka H; Hirakawa K; Tahara K; Shimizu R; Ozasa H; Etoh R; Sugiura F; Okuno K; Furuya T; Nishimura T; Sakata K; Yoshimatsu K; Takenouchi H; Tsunedomi R; Inoue Y; Kanekiyo S; Shindo Y; Suzuki N; Yoshino S; Shinozaki H; Kamiya A; Furukawa H; Yamanaka T; Fujita T; Kawakami Y; Oka M
    J Transl Med; 2014 Apr; 12():108. PubMed ID: 24884643
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
    Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
    J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.
    Oji Y; Tatsumi N; Fukuda M; Nakatsuka S; Aoyagi S; Hirata E; Nanchi I; Fujiki F; Nakajima H; Yamamoto Y; Shibata S; Nakamura M; Hasegawa K; Takagi S; Fukuda I; Hoshikawa T; Murakami Y; Mori M; Inoue M; Naka T; Tomonaga T; Shimizu Y; Nakagawa M; Hasegawa J; Nezu R; Inohara H; Izumoto S; Nonomura N; Yoshimine T; Okumura M; Morii E; Maeda H; Nishida S; Hosen N; Tsuboi A; Oka Y; Sugiyama H
    Int J Oncol; 2014 May; 44(5):1461-9. PubMed ID: 24589652
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Dendritic cell-based immunotherapy for colon cancer using an hla-a*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
    Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
    Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.
    Nobuoka D; Yoshikawa T; Takahashi M; Iwama T; Horie K; Shimomura M; Suzuki S; Sakemura N; Nakatsugawa M; Sadamori H; Yagi T; Fujiwara T; Nakatsura T
    Cancer Immunol Immunother; 2013 Apr; 62(4):639-52. PubMed ID: 23143746
    [TBL] [Abstract] [Full Text] [Related]  


    of 2.